Strides Pharma Science Limited – Q4 FY26 Results

key financial highlights

• Revenue from Operations:
  • Revenue (Q4 FY26): ₹1,323.47 crore
    • QoQ Change: +10.8%
    • YoY Change: +11.2%
  • Previous Quarter (Q3 FY26): ₹1,194.65 crore
  • Previous Year (Q4 FY25): ₹1,190.39 crore
• Profit After Tax (PAT):
  • PAT (Q4 FY26): ₹129.28 crore
    • QoQ Change: -37.9%
    • YoY Change:+51.0%
  • Previous Quarter (Q3 FY26): ₹208.12 crore
  • Previous Year (Q4 FY25): ₹85.62 crore
• QoQ Performance:
  • Revenue:
    • Revenue growth remained healthy across key pharmaceutical operations.
    • Sequential growth was supported by improved product mix and operational execution.
    • Annual revenue crossed ₹4,858.68 crore.
      
  • Profit:
    • Quarterly profitability moderated sequentially after a strong Q3.
    • YoY profitability improved sharply due to operational efficiency and lower exceptional impact.
    • FY26 PAT rose strongly to ₹574.52 crore.

Margin Analysis

Drivers:

• Gross profitability improved due to better product mix.
• Finance costs reduced significantly on a yearly basis.
• Employee expenses increased due to operational scaling.
• Other expenses remained elevated due to business expansion activities.
• Inventory adjustments positively supported margins.

Insight:

• The company demonstrated meaningful operating leverage and profitability recovery despite elevated financing and compliance costs.

Segment insight

Business Summary:

Strides Pharma continues to focus on regulated pharmaceutical markets with emphasis on operational efficiency, manufacturing scale, and balance sheet repair.

Key Characteristics:

• Export-oriented pharmaceutical business model.
• Strong focus on regulated generics markets.
• Deleveraging-driven financial strategy.
• Improving operational cash generation profile.

Earning quality check

Key Drivers:

• Net cash generated from operating activities improved to ₹702.52 crore.
• Operating profit before working capital changes increased strongly.
• Working capital pressures persisted due to inventories and receivables.
• Interest costs declined materially YoY.
• Exceptional losses reduced significantly versus previous year.

Interpretations:

• Earnings quality improved materially during FY26 as operational cash generation strengthened and debt servicing burden reduced.

balance sheet Analysis

• Total Assets: ₹6,927.23 crore
• Total Liabilities: ₹3,777.90 crore

Insight:

• Equity base strengthened materially due to profit growth.
• Cash and cash equivalents improved sharply to ₹188.70 crore.
• Borrowings reduced compared with prior year.
• Current assets increased due to inventory expansion and receivable growth.

key risks

• Regulatory risks in global pharmaceutical markets.
• Pricing pressure in generics business.
• Working capital intensity remains elevated.
• Currency fluctuations can impact export profitability.
• Dependence on regulated market approvals.

management strategy signals

Focus Area:

• Continued debt reduction and deleveraging.
• Improving profitability through product mix optimization.
• Strengthening regulated market presence.
• Expanding manufacturing efficiency.
• Enhancing cash flow generation.

Financial metrics table

Quarterly Performance Context